P.R. Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.20 Cr
as on 05-07-2024
- Paid Up Capital ₹ 0.83 Cr
as on 05-07-2024
- Company Age 34 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 13.74 Cr
as on 05-07-2024
- Revenue %
(FY 2023)
- Profit -1332.56%
(FY 2023)
- Ebitda -1332.56%
(FY 2023)
- Net Worth -26.67%
(FY 2023)
- Total Assets -5.83%
(FY 2023)
About P.R. Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 Cr and a paid-up capital of Rs 0.83 Cr.
The company has closed loans amounting to ₹13.74 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Babu Vedulla and Kishore Vedulla serve as directors at the Company.
- CIN/LLPIN
U24111KA1990PTC010978
- Company No.
010978
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jun 1990
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bidar, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at P.R. Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Babu Vedulla  | Director | 17-Mar-2014 | Current |
| Kishore Vedulla | Director | 17-Mar-2014 | Current |
Financial Performance and Corporate Structure Insights of P.R. Drugs.
P.R. Drugs Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1332.56% decrease in profit. The company's net worth observed a substantial decline by a decrease of 26.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of P.R. Drugs?
In 2023, P.R. Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
1 year 4 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 28 Mar 2016 | ₹3.65 Cr | Satisfied |
State Bank Of India Creation Date: 19 Nov 2012 | ₹5.30 Cr | Satisfied |
Nkgsb Co-Op. Bank Limited Creation Date: 11 Mar 2011 | ₹1.00 Cr | Satisfied |
How Many Employees Work at P.R. Drugs?
Unlock and access historical data on people associated with P.R. Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Mar 26, 2012, P.R. Drugs has raised a total of ₹ 1.11 Cr, with the most recent deal valued at ₹ 5.57 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
